On heels of pos­i­tive da­ta for AT­TR drug, Al­ny­lam looks to raise more cap­i­tal — near­ly $1B worth

A week af­ter pre­sent­ing pos­i­tive da­ta on its drug for treat­ing the heart fail­ure con­di­tion called transthyretin-me­di­at­ed amy­loi­do­sis (AT­TR) with car­diomy­opa­thy, Al­ny­lam wants to get al­most $1 bil­lion in new mon­ey.

The com­pa­ny an­nounced that it was of­fer­ing a $900 mil­lion prin­ci­pal amount of con­vert­ible se­nior notes due 2027. Con­vert­ible notes are short-term debt that con­verts in­to eq­ui­ty.

“The of­fer­ing of the notes is sub­ject to mar­ket and oth­er con­di­tions and there can be no as­sur­ance as to whether or when the of­fer­ing may be com­plet­ed, or as to the ac­tu­al size or terms of the of­fer­ing,” the com­pa­ny said in a press state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.